Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 May 27:24:3524-3530.
doi: 10.12659/MSM.907798.

Expression of Fibroblast Growth Factor 5 (FGF5) and Its Influence on Survival of Breast Cancer Patients

Yuanli Huang  1 , Hongtao Wang  2 , Yuanrong Yang  2
Affiliations

Expression of Fibroblast Growth Factor 5 (FGF5) and Its Influence on Survival of Breast Cancer Patients

Yuanli Huang et al. Med Sci Monit. .

Abstract

BACKGROUND The clinical outcome of patients with breast cancer (BC) remains poor. MATERIAL AND METHODS We analyzed BC microarray studies GSE37751, GSE7390, and GSE21653 to investigate the expression of FGF5 gene between BC patients and their normal counterparts and the relationship between FGF5 expression and age, tumor size, histopathological grading, estrogen receptors, clinical risk group according to St Gallen criteria, clinical risk group according to NPI criteria, clinical risk group according to Veridex signature, distant metastasis-free survival (DMFS), time to distant metastasis (TDM), disease-free survival (DFS), and overall survival (OS) of BC patients. Gene set enrichment analysis (GSEA) was used to investigate the exact mechanisms. RESULTS FGF5 expression was significantly upregulated in BC patients relative to that in normal controls (P<0.0001). BC patients in the FGF5 low-expression group were correlated with better clinical characteristics, including tumor size, histopathological grading, estrogen receptors, clinical risk group according to St Gallen criteria, NPI criteria and Veridex signature, DMFS, TDM, and DFS compared with those in the FGF5 high-expression cohort. The result of GSEA indicated that FGF5 inhibits the proliferation of BC cells via ultraviolet response and TGF-b signaling. Quantitative PCR verified that FGF5 was overexpressed in patients with BC. CONCLUSIONS Our results suggest that FGF5 is an independent protective factor for BC patients.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

None.

Figures

Figure 1
Figure 1
The expression of FGF5 in breast cancers and normal breast cancer tissues.
Figure 2
Figure 2
The relationship between the expression of FGF5 and the clinical prognosis of patients with breast cancer. (A) Distant metastasis-free survival; (B) time to distant metastasis; (C) disease-free survival; (D) overall survival.
Figure 3
Figure 3
Gene sets enriched in breast cancer patients in the FGF5 high-expression group. (A) ultraviolet response, (B) TGF-β signaling.
Figure 4
Figure 4
FGF5 was upregulated in patients with BC.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Sanli O, Dobruch J, Knowles MA, et al. Bladder cancer. Nat Rev Dis Primers. 2017;3:17022. - PubMed
    1. da Costa Vieira RA, Biller G, Uemura G, Ruiz CA, Curado MP. Breast cancer screening in developing countries. Clinics (Sao Paulo) 2017;72(4):244–53. - PMC - PubMed
    1. Ogunsiji OO, Kwok C, Fan LC. Breast cancer screening practices of African migrant women in Australia: A descriptive cross-sectional study. BMC Womens Health. 2017;17(1):32. - PMC - PubMed
    1. Coleman C. Early detection and screening for breast cancer. Semin Oncol Nurs. 2017;33(2):141–55. - PubMed
    1. Mislang AR, Cheung KL, Hamaker ME, et al. Controversial issues in the management of older adults with early breast cancer. J Geriatr Oncol. 2017;8(6):397–402. - PubMed

Substances